We developed a new base caller DeepNano-coral for nanopore sequencing, which is optimized to run on the Coral Edge Tensor Processing Unit, a small USB-attached hardware accelerator. To achieve this goal, we have designed ne
In nanopore sequencing, electrical signal is measured as DNA molecules pass through the sequencing pores. Translating these signals into DNA bases (base calling) is a highly non-trivial task, and its quality has a large impact on the sequencing accur
acy. The most successful nanopore base callers to date use convolutional neural networks (CNN) to accomplish the task. Convolutional layers in CNNs are typically composed of filters with constant window size, performing best in analysis of signals with uniform speed. However, the speed of nanopore sequencing varies greatly both within reads and between sequencing runs. Here, we present dynamic pooling, a novel neural network component, which addresses this problem by adaptively adjusting the pooling ratio. To demonstrate the usefulness of dynamic pooling, we developed two base callers: Heron and Osprey. Heron improves the accuracy beyond the experimental high-accuracy base caller Bonito developed by Oxford Nanopore. Osprey is a fast base caller that can compete in accuracy with Guppy high-accuracy mode, but does not require GPU acceleration and achieves a near real-time speed on common desktop CPUs. Availability: https://github.com/fmfi-compbio/osprey, https://github.com/fmfi-compbio/heron Keywords: nanopore sequencing, base calling, convolutional neural networks, pooling
Nanopore genome sequencing is the key to enabling personalized medicine, global food security, and virus surveillance. The state-of-the-art base-callers adopt deep neural networks (DNNs) to translate electrical signals generated by nanopore sequencer
s to digital DNA symbols. A DNN-based base-caller consumes $44.5%$ of total execution time of a nanopore sequencing pipeline. However, it is difficult to quantize a base-caller and build a power-efficient processing-in-memory (PIM) to run the quantized base-caller. In this paper, we propose a novel algorithm/architecture co-designed PIM, Helix, to power-efficiently and accurately accelerate nanopore base-calling. From algorithm perspective, we present systematic error aware training to minimize the number of systematic errors in a quantized base-caller. From architecture perspective, we propose a low-power SOT-MRAM-based ADC array to process analog-to-digital conversion operations and improve power efficiency of prior DNN PIMs. Moreover, we revised a traditional NVM-based dot-product engine to accelerate CTC decoding operations, and create a SOT-MRAM binary comparator array to process read voting. Compared to state-of-the-art PIMs, Helix improves base-calling throughput by $6times$, throughput per Watt by $11.9times$ and per $mm^2$ by $7.5times$ without degrading base-calling accuracy.
Motivation: The MinION device by Oxford Nanopore is the first portable sequencing device. MinION is able to produce very long reads (reads over 100~kBp were reported), however it suffers from high sequencing error rate. In this paper, we show that th
e error rate can be reduced by improving the base calling process. Results: We present the first open-source DNA base caller for the MinION sequencing platform by Oxford Nanopore. By employing carefully crafted recurrent neural networks, our tool improves the base calling accuracy compared to the default base caller supplied by the manufacturer. This advance may further enhance applicability of MinION for genome sequencing and various clinical applications. Availability: DeepNano can be downloaded at http://compbio.fmph.uniba.sk/deepnano/. Contact: [email protected]
The emerging field of precision oncology relies on the accurate pinpointing of alterations in the molecular profile of a tumor to provide personalized targeted treatments. Current methodologies in the field commonly include the application of next ge
neration sequencing technologies to a tumor sample, followed by the identification of mutations in the DNA known as somatic variants. The differentiation of these variants from sequencing error poses a classic classification problem, which has traditionally been approached with Bayesian statistics, and more recently with supervised machine learning methods such as neural networks. Although these methods provide greater accuracy, classic neural networks lack the ability to indicate the confidence of a variant call. In this paper, we explore the performance of deep Bayesian neural networks on next generation sequencing data, and their ability to give probability estimates for somatic variant calls. In addition to demonstrating similar performance in comparison to standard neural networks, we show that the resultant output probabilities make these better suited to the disparate and highly-variable sequencing data-sets these models are likely to encounter in the real world. We aim to deliver algorithms to oncologists for which model certainty better reflects accuracy, for improved clinical application. By moving away from point estimates to reliable confidence intervals, we expect the resultant clinical and treatment decisions to be more robust and more informed by the underlying reality of the tumor molecular profile.
The genomic profile underlying an individual tumor can be highly informative in the creation of a personalized cancer treatment strategy for a given patient; a practice known as precision oncology. This involves next generation sequencing of a tumor
sample and the subsequent identification of genomic aberrations, such as somatic mutations, to provide potential candidates of targeted therapy. The identification of these aberrations from sequencing noise and germline variant background poses a classic classification-style problem. This has been previously broached with many different supervised machine learning methods, including deep-learning neural networks. However, these neural networks have thus far not been tailored to give any indication of confidence in the mutation call, meaning an oncologist could be targeting a mutation with a low probability of being true. To address this, we present here a deep bayesian recurrent neural network for cancer variant calling, which shows no degradation in performance compared to standard neural networks. This approach enables greater flexibility through different priors to avoid overfitting to a single dataset. We will be incorporating this approach into software for oncologists to obtain safe, robust, and statistically confident somatic mutation calls for precision oncology treatment choices.